Gefitinib is widely used for the treatment of lung cancer in patients with sensitizing epidermal growth factor receptor mutations,but patients tend to develop resistance after an average of 10 months.Low molecular wei...Gefitinib is widely used for the treatment of lung cancer in patients with sensitizing epidermal growth factor receptor mutations,but patients tend to develop resistance after an average of 10 months.Low molecular weight heparins,such as enoxaparin,potently inhibit experimental metastasis.This study aimed to determine the potential of combined enoxaparin and gefitinib(enoxaparin+gefitinib)treatment to inhibit tumor resistance to gefitinib both in vitro and in vivo.A549 and H1975 cell migration was analyzed in wound closure and Transwell assays.Akt and extracellular signal related kinase 1/2(Erk1/2)signaling pathways were identified,and a proteomics analysis was conducted using SDSPAGE/liquid chromatography-tandem mass spectrometry analysis.Molecular interaction networks were visualized using the cytoscape bioinformatics platform.Protein expression of dedicator of cytokinesis1(DOCK1)and cytoskeleton intermediate filament vimentin were identified using an enzyme-linked immunosorbent assay,Western blotting,and small interfering RNA transfection of A549 cells.In xenograft A549-luc-C8 tumors in nude mice,enoxaparin+gefitinib inhibited tumor growth and reduced lung colony formation compared with gefitinib alone.Furthermore,the combination had stronger inhibitory effects on cell migration than either agent used individually.Additional enoxaparin administration resulted in better effective inhibition of Akt activity compared with gefitinib alone.Proteomics and network analysis implicated DOCK1 as the key node molecule.Western blot verified the effective inhibition of the expression of DOCK1 and vimentin phosphorylation by enoxaparin+gefitinib comparedwith gefitinib alone.DOCK1 knockdown confirmed its role in cell migration,Akt expression,and vimentin phosphorylation.Our data indicate that enoxaparin sensitizes gefitinib antitumor and antimigration activity in lung cancer by suppressing DOCK1 expression,Akt activity,and vimentin phosphorylation.展开更多
文摘Gefitinib is widely used for the treatment of lung cancer in patients with sensitizing epidermal growth factor receptor mutations,but patients tend to develop resistance after an average of 10 months.Low molecular weight heparins,such as enoxaparin,potently inhibit experimental metastasis.This study aimed to determine the potential of combined enoxaparin and gefitinib(enoxaparin+gefitinib)treatment to inhibit tumor resistance to gefitinib both in vitro and in vivo.A549 and H1975 cell migration was analyzed in wound closure and Transwell assays.Akt and extracellular signal related kinase 1/2(Erk1/2)signaling pathways were identified,and a proteomics analysis was conducted using SDSPAGE/liquid chromatography-tandem mass spectrometry analysis.Molecular interaction networks were visualized using the cytoscape bioinformatics platform.Protein expression of dedicator of cytokinesis1(DOCK1)and cytoskeleton intermediate filament vimentin were identified using an enzyme-linked immunosorbent assay,Western blotting,and small interfering RNA transfection of A549 cells.In xenograft A549-luc-C8 tumors in nude mice,enoxaparin+gefitinib inhibited tumor growth and reduced lung colony formation compared with gefitinib alone.Furthermore,the combination had stronger inhibitory effects on cell migration than either agent used individually.Additional enoxaparin administration resulted in better effective inhibition of Akt activity compared with gefitinib alone.Proteomics and network analysis implicated DOCK1 as the key node molecule.Western blot verified the effective inhibition of the expression of DOCK1 and vimentin phosphorylation by enoxaparin+gefitinib comparedwith gefitinib alone.DOCK1 knockdown confirmed its role in cell migration,Akt expression,and vimentin phosphorylation.Our data indicate that enoxaparin sensitizes gefitinib antitumor and antimigration activity in lung cancer by suppressing DOCK1 expression,Akt activity,and vimentin phosphorylation.
